Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07888504
PHASE4

Low-Dose Spironolactone in Hemodialysis Patients With Resistant Hypertension

Sponsor: Universitas Sebelas Maret

View on ClinicalTrials.gov

Summary

Many patients on hemodialysis have high blood pressure that does not respond to three or more drugs (resistant hypertension). This pilot study gave a low dose of spironolactone (12.5 mg once daily) for 6 weeks to adults on hemodialysis with resistant hypertension. The study measured changes in blood pressure, heart rate variability, markers of inflammation (interleukin-6 and high-sensitivity C-reactive protein), a marker of cardiac stress (NT-proBNP), and serum potassium.

Official title: Low-Dose Spironolactone and Changes in Blood Pressure, Heart Rate Variability, and Inflammatory and Cardiac Biomarkers in Hemodialysis Patients With Resistant Hypertension: A Single-Arm Pre-Post Study

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

21

Start Date

2024-08-20

Completion Date

2024-10-31

Last Updated

2026-10-22

Healthy Volunteers

No

Interventions

DRUG

Spironolactone

Spironolactone 12.5 mg taken orally once daily for 6 weeks.

Locations (1)

Dr. Moewardi General Hospital

Surakarta, Central Java, Indonesia